IDEXX Laboratories, Inc. announced the launch of its Catalyst Cortisol Test, marking the third menu expansion for the Catalyst platform in under a year. This new test provides veterinarians with real-time quantitative cortisol concentrations, crucial for diagnosing Addison's disease and managing Cushing's syndrome in dogs. The test aims to deliver critical insights at the point-of-care, enhancing diagnostic capabilities for veterinary practices.
Addison's disease and Cushing's syndrome are significant endocrine disorders in dogs, with early and accurate diagnosis being vital for effective treatment and management. The Catalyst Cortisol Test offers in-clinic results that align with IDEXX Reference Laboratories, providing veterinarians with confidence in their diagnostic decisions and supporting immediate treatment adjustments.
The Catalyst Cortisol Test will become available in the U.S. and Canada by the end of July 2025. A global rollout to the extensive installed base of over 75,000 Catalyst chemistry analyzers is anticipated to commence in the third quarter of 2025, further expanding the recurring revenue stream associated with the Catalyst platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.